{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blaine-Sauer S"],"funding":["Mr. Eric Becker and his family","Dr. Jamie Koufman","Medical College of Wisconsin Department of Otolaryngology and Communication Sciences"],"pagination":["6765"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10095080"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(7)"],"pubmed_abstract":["Gastroesophageal reflux disease (GERD) significantly impacts patient quality of life and is a major risk factor for the development of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). Proton pump inhibitors (PPIs) are the standard-of-care for GERD and are among the most prescribed drugs in the world, but do not protect against nonacid components of reflux such as pepsin, or prevent reflux-associated carcinogenesis. We recently identified an HIV protease inhibitor amprenavir that inhibits pepsin and demonstrated the antireflux therapeutic potential of its prodrug fosamprenavir in a mouse model of laryngopharyngeal reflux. In this study, we assessed the capacity of amprenavir to protect against esophageal epithelial barrier disruption in vitro and related molecular events, E-cad"],"journal":["International journal of molecular sciences"],"pubmed_title":["The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes."],"pmcid":["PMC10095080"],"funding_grant_id":["N/A","Donation"],"pubmed_authors":["Yan K","Blaine-Sauer S","Samuels TL","Johnston N"],"additional_accession":[]},"is_claimable":false,"name":"The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.","description":"Gastroesophageal reflux disease (GERD) significantly impacts patient quality of life and is a major risk factor for the development of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). Proton pump inhibitors (PPIs) are the standard-of-care for GERD and are among the most prescribed drugs in the world, but do not protect against nonacid components of reflux such as pepsin, or prevent reflux-associated carcinogenesis. We recently identified an HIV protease inhibitor amprenavir that inhibits pepsin and demonstrated the antireflux therapeutic potential of its prodrug fosamprenavir in a mouse model of laryngopharyngeal reflux. In this study, we assessed the capacity of amprenavir to protect against esophageal epithelial barrier disruption in vitro and related molecular events, E-cad","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-07-10T03:08:13.159Z","creation":"2025-04-04T12:15:41.3Z"},"accession":"S-EPMC10095080","cross_references":{"pubmed":["37047737"],"doi":["10.3390/ijms24076765"]}}